Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $32.5 million.

  • Phathom Pharmaceuticals' Non-Current Assets rose 14582.92% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.3 million, marking a year-over-year increase of 8432.44%. This contributed to the annual value of $18.2 million for FY2024, which is 1081.05% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Non-Current Assets of $32.5 million as of Q3 2025, which was up 14582.92% from $31.3 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Non-Current Assets peaked at $32.5 million during Q3 2025, and registered a low of $3.3 million during Q1 2022.
  • Moreover, its 4-year median value for Non-Current Assets was $13.2 million (2024), whereas its average is $14.0 million.
  • Within the past 5 years, the most significant YoY rise in Phathom Pharmaceuticals' Non-Current Assets was 28840.89% (2024), while the steepest drop was 1081.05% (2024).
  • Phathom Pharmaceuticals' Non-Current Assets (Quarter) stood at $4.3 million in 2022, then surged by 281.81% to $16.4 million in 2023, then increased by 10.81% to $18.2 million in 2024, then soared by 78.76% to $32.5 million in 2025.
  • Its last three reported values are $32.5 million in Q3 2025, $31.3 million for Q2 2025, and $29.3 million during Q1 2025.